Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 3 Interventional

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

ClinicalTrials.gov ID: NCT07680790

Public ClinicalTrials.gov record NCT07680790. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer

Study identification

NCT ID
NCT07680790
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
850 participants

Conditions and interventions

Interventions

  • Iza-bren Drug
  • Osimertinib Drug
  • Pemetrexed Drug
  • Carboplatin Drug
  • Cisplatin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 29, 2026
Primary completion
Dec 29, 2031
Completion
Dec 29, 2031
Last update posted
Jul 14, 2026

2026 – 2031

United States locations

U.S. sites
34
U.S. states
23
U.S. cities
33
Facility City State ZIP Site status
Local Institution - 0212 Beverly Hills California 90211
Local Institution - 0504 Fullerton California 92835
Local Institution - 0357 La Jolla California 92093
Local Institution - 0520 Pueblo Colorado 81003
Local Institution - 0527 Fort Myers Florida 33901
Local Institution - 0366 Orlando Florida 32806
Local Institution - 0519 Palm Bay Florida 32901
Local Institution - 0210 Honolulu Hawaii 96813
Local Institution - 0207 Ottawa Illinois 61350
Local Institution - 0503 Baltimore Maryland 21202
Local Institution - 0523 Silver Spring Maryland 20904
Local Institution - 0521 Edina Minnesota 55435
Local Institution - 0364 Saint Paul Minnesota 55102
Local Institution - 0403 St Louis Missouri 63110
Local Institution - 0402 Omaha Nebraska 68198
Local Institution - 0290 Lebanon New Hampshire 03756
Local Institution - 0183 New Brunswick New Jersey 08901
Local Institution - 0153 New York New York 10021
Local Institution - 0157 The Bronx New York 10461
Local Institution - 0385 Charlotte North Carolina 28204
Local Institution - 0438 Sandusky Ohio 44870
Local Institution - 0404 Portland Oregon 97213
Local Institution - 0487 Easton Pennsylvania 18045
Local Institution - 0200 Sioux Falls South Dakota 57105
Local Institution - 0199 Memphis Tennessee 38120
Local Institution - 0522 Beaumont Texas 77702
Local Institution - 0525 Dallas Texas 75246
Local Institution - 0529 San Antonio Texas 78217
Local Institution - 0411 Salt Lake City Utah 84112
Local Institution - 0165 Fairfax Virginia 22031
Local Institution - 0530 Fairfax Virginia 22031
Local Institution - 0528 Winchester Virginia 22601
Local Institution - 0283 Seattle Washington 98104
Local Institution - 0502 Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 166 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07680790, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 14, 2026 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07680790 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →